CENTERED ON INNOVATION
CD20 IV
CD19 CAR-T
CD20 SUB-Q
Ublituximab is a novel, glycoengineered monoclonal antibody designed to selectively target a unique epitope on CD20-expressing B cells. CD20 is a well-validated therapeutic target found on the surface of pre-B and mature B lymphocytes, which play a central role in the pathogenesis of multiple autoimmune diseases and B-cell malignancies.
Upon binding to CD20, ublituximab initiates several immune-mediated mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to efficient depletion of CD20 expressing B cells. Ublituximab has been glycoengineered to remove specific fucose sugar residues from the Fc region of the antibody. This structural modification enhances binding affinity to Fc gamma receptors on immune effector cells, resulting in increased ADCC activity and improved potency compared to non-glycoengineered anti-CD20 antibodies.
Targeting CD20 with monoclonal antibodies has become a cornerstone therapeutic strategy across a range of B-cell-driven conditions, including autoimmune disorders and hematologic malignancies. Ublituximab is currently approved (under the brand name, BRIUMVI) for relapsing forms of multiple sclerosis and being investigated in other B-cell mediated autoimmune conditions.
Please click here to view our Publications Page.
